<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T06:29:08Z</responseDate>
  <request identifier="oai:figshare.com:article/31898371" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/31898371</identifier>
        <datestamp>2026-09-30T21:52:53Z</datestamp>
        <setSpec>category_27052</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Figure 1 - Zambia TAS 1 LF Wb Ag prevalence by EU (n=25 EUs)</dc:title>
          <dc:creator>Belem B. Matapo (23650909)</dc:creator>
          <dc:subject>Epidemiological methods</dc:subject>
          <dc:subject>Lymphatic Filariasis</dc:subject>
          <dc:subject>Wb Ag</dc:subject>
          <dc:subject>TAS-1</dc:subject>
          <dc:subject>EU</dc:subject>
          <dc:subject>Zambia</dc:subject>
          <dc:description>&lt;p dir="ltr"&gt;This figure presents the &lt;i&gt;Wuchereria bancrofti&lt;/i&gt; antigen (Wb Ag) prevalence estimates for all 25 Evaluation Units (EUs) surveyed during Zambia’s first Transmission Assessment Survey (TAS‑1). Prevalence values are based on antigen testing of learners in grades 1 and 2 using WHO‑recommended diagnostic tools. The figure provides a comparative overview of EU‑level transmission intensity and supports the interpretation of TAS‑1 classification outcomes relative to the WHO-recommended target of &lt;2% prevalence per EU. &lt;/p&gt;</dc:description>
          <dc:date>2026-03-31T07:16:28Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.6084/m9.figshare.31898371.v9</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/Figure_1_-_Zambia_TAS_1_LF_Wb_Ag_prevalence_by_EU_n_25_EUs_/31898371</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
